Dr. Weisel on the Safety Profile of Isa-KRd in High-Risk Multiple Myeloma

Katja Weisel, MD, of the University Hospital Hamburg, discusses the safety profile of isatuximab-irfc (Sarclisa) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Isa-KRd) in high-risk patients with newly diagnosed multiple myeloma.

An interim analysis of the phase 2 GMMG-Concept trial (NCT03104842) presented at the 2020 European Hematology Association Congress demonstrated a 100% overall response rate and high rates of minimal residual disease negativity in this patient population, regardless of transplant eligibility.

The main treatment-emergent adverse events (TEAEs) were hematologic in nature, explains Weisel. Grade 3/4 neutropenia was observed in 34% of patients, and grade 3/4 thrombocytopenia occurred in 14% of patients.

Common non-hematologic TEAEs were as expected, says Weisel. Grade 3/4 hypertension occurred in 12% of patients and was likely due to carfilzomib.

Additionally, the rates of all-grade and grade 3/4 peripheral sensory neuropathy were low at 16% and 2%, respectively. Any-grade infusion-related reactions were observed in 32% of patients and all were grade 1 or 2 in nature.